Találati lista | Tudóstér

001-es BibID:	BIBFORM005181
035-os BibID:	(scopus)40149107884 (wos)000255092200005
Első szerző:	Friedländer Elza (biofizikus)
Cím:	ErbB-directed immunotherapy : antibodies in current practice and promising new agents / Elza Friedländer, Márk Barok, János Szöllősi, György Vereb
Dátum:	2008
Megjegyzések:	The ErbB family is well known for its significance in oncogenesis. As bad prognostic markers, overexpressed or mutated ErbB1 and ErbB2 have an important role in the molecular diagnosis of various cancers, but as membrane proteins, expressed often selectively in tumor tissues, they can be targeted with kinase inhibitors or therapeutic antibodies. In addition to trastuzumab, the first humanized antibody that was approved for the therapy of solid tumors by the FDA, now many humanized antibodies are in late clinical trials, or already approved. Conjugation of antibodies with radioactive isotopes, cytotoxic agents or liposomes loaded with chemotherapeutic drugs led to improved therapeutic efficiency over their parent "unarmed" antibodies. Novel, engineered antibody derivates with better pharmacodynamic properties are also available and allow the targeting of ErbB1 or ErbB2 positive cancers in a wider patient population. In this review, we discuss the biological and clinical background of ErbB targeting, and describe the most successful antibodies against ErbB1 (cetuximab, panitumumab, matuzumab, nimotuzumab, ICR62, mAb 528, ch806 and MDX-447) and ErbB2 (trastuzumab, pertuzumab, MDX-H210, 2B1, C6.5xscFv(NM3E2), ertumaxomab and FRP-5 derivates) that are in clinical trials or already approved, along with the various relevant conjugation and engineering strategies. Recent data pertinent to the prevalent problem of clinical resistance to treatment with trastuzumab are also discussed.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk agonists analysis Animal Antibodies Antibody conjugation Antibody targeted delivery Apoptosis Biophysics Brain Carcinoma Cell Line Cell Proliferation Cell Survival Cells Clinical trial Cysteine diagnosis Dimerization Down-Regulation Drug Resistance EGFR Endocytosis Engineered antibody Epidermal Growth Factor Epitopes ErbB1 ErbB2 Fibroblasts Glioblastoma Glioma Human Humanized antibody Hungary In Vitro Insulin Membrane Proteins Mice Microscopy Microspheres Mutation Necrosis Paclitaxel Phenotype Phosphorylation Prevalence Progesterone Proteins radiotherapy Research Signal Transduction therapy toxicity Trastuzumab resistance Tumor Necrosis Factor Tumor therapy/cancer therapy Tyrosine Up-Regulation
Megjelenés:	Immunology Letters. - 116 : 2 (2008), p. 126-140. -
További szerzők:	Barok Márk (1976-) (biofizikus) Szöllősi János (1953-) (biofizikus) Vereb György (1965-) (biofizikus, orvos)
Internet cím:	elektronikus változat DOI elektronikus változat
Borító:
Saját polcon: